at CNBC.com (May 5, 2011)
Sagent Pharmaceuticals (SGNT) announces the approval and launch of its Zoledronic Acid Injection, the generic form of Zometa, in a plastic vial. The U.S. market for Zoledronic Acid Injection is approximately $606M. Additionally, the company says its amended its manufacturing and supply agreement with Actavis (ACT) which provides for an enhanced profit split in favor of SGNT, plus a revised line-up of products and a one-time termination fee of $5 million payable to Sagent.
From other sites